文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤CAR-T细胞治疗后的输血需求:预测因素与结局(DESCAR-T研究)

Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).
PubMed 文献 · Blood Adv · 2024-01-01

该研究基于法国DESCAR-T注册中心671例接受CD19 CAR-T细胞治疗的大B细胞淋巴瘤患者,分析输血需求及预测因素。CAR-T输注前6个月401例(59.8%)和输注后6个月378例(56.3%)接受输血。早期输血及晚期血小板(非红细胞)输血与更短的无进展生存和总生存相关。

要点

  • CAR-T输注后6个月内56.3%患者接受输血,早期输血高峰在输注后第1个月。
  • 早期输血预测因素包括年龄>60岁、ECOG PS≥2、阿基仑赛、CAR-T前输血、CAR-HEMATOTOX评分≥2。
  • 早期输血及晚期血小板输血与更短无进展生存和总生存相关,输血人群淋巴瘤相关死亡和非复发死亡均增加。

核心结论

  • CAR-T治疗后早期和晚期输血需求有不同预测因素,早期输血及晚期血小板输血与更短的无进展生存和总生存相关。

研究设计与样本

  • 回顾性分析法国DESCAR-T注册中心671例接受CD19 CAR-T细胞治疗且输血数据完整的复发/难治性大B细胞淋巴瘤患者。

主要发现

  • CAR-T输注前6个月401例(59.8%)和输注后6个月378例(56.3%)患者接受输血。
  • 输血患者数和平均输血产品数在CAR-T输注前6个月增加,输注后第1个月达峰,随后随时间下降。
  • 早期输血预测因素为年龄>60岁、ECOG PS≥2、阿基仑赛治疗、CAR-T前输血、CAR-HEMATOTOX评分≥2。
  • 晚期输血(输注后1至6个月)预测因素为CAR-T前输血、CAR-HEMATOTOX评分≥2、ICANS≥3(红细胞输血)和托珠单抗使用(血小板输血)。
  • 早期输血和晚期血小板(非红细胞)输血与更短的无进展生存和总生存相关;输血人群淋巴瘤相关死亡和非复发死亡均增加。

关键数值与推荐

  • CAR-T前6个月输血:401/671例(59.8%);CAR-T后6个月输血:378/671例(56.3%)。
  • 早期输血预测因素:年龄>60岁、ECOG PS≥2、阿基仑赛、CAR-T前输血、CAR-HEMATOTOX评分≥2。
  • 晚期输血预测因素:CAR-T前输血、CAR-HEMATOTOX评分≥2、ICANS≥3(红细胞)、托珠单抗使用(血小板)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent CAR T-cell-related adverse event. Transfusion support is a surrogate marker of severe cytopenias. Transfusion affects patients' quality of life, presents specific toxicities, and is known to affect immunity through the so-called transfusion-related immunomodulation that may affect CAR T-cell efficacy. We analyzed data from 671 patients from the French DESCAR-T registry for whom exhaustive transfusion data were available. Overall, 401 (59.8%) and 378 (56.3%) patients received transfusion in the 6-month period before and after CAR T-cell infusion, respectively. The number of patients receiving transfusion and the mean number of transfused products increased during the 6-month period before CAR T-cell infusion, peaked during the first month after infusion (early phase), and decreased over time. Predictive factors for transfusion at the early phase were age >60 years, ECOG PS ≥2, treatment with axicabtagene ciloleucel, pre-CAR T-cell transfusions, and CAR-HEMATOTOX score ≥2. Predictive factors for late transfusion (between 1 and 6 months after infusion) were pre-CAR T-cell transfusions, CAR-HEMATOTOX score ≥2, ICANS ≥3 (for red blood cells [RBC] transfusion), and tocilizumab use (for platelets transfusion). Early transfusions and late platelets (but not RBC) transfusions were associated with a shorter progression-free survival and overall survival. Lymphoma-related mortality and nonrelapse mortality were both increased in the transfused population. Our data shed light on the mechanisms of early and late cytopenia and on the potential impact of transfusions on CAR T-cell efficacy and toxicity.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vic S, Thibert JB, Bachy E, et al. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study). Blood Adv. 2024. PMID: 38181767. doi:10.1182/bloodadvances.2023011727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。